Aktienanalyse zu Seer Inc (SEER)SEERSeer Inc

Seer, Inc. is a life sciences company. It is developing products that open a new gateway to the proteome. Its Proteograph product suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform proteomic analysis at scale in a matter of hours. The Proteograph has detected over 36,000 proteins across multiple species, and its performance and capabilities have been demonstrated in over 33 peer-reviewed publications, preprints and reviews. The Proteograph Product Suite is detector-agnostic and is adaptable to other protein detection instruments. The MS component of the Proteograph workflow is either provided by the researcher’s laboratory, can be outsourced to a third-party provider, or be run through the Seer Technology Access Center (STAC), which is its in-house service program. It has launched Proteograph XT, which enhances the sample throughput of the Proteograph Product Suite and MS instrument. It operates in the Technology sector (LABORATORY ANALYTICAL INSTRUMENTS industry).

Seer Inc is a good buy right now due to its current price of $2.03, which is significantly lower than the analyst price target of $4, indicating a potential upside of 96.56%. Additionally, the stock has a gross margin of 48.55%, showing solid profitability potential despite recent losses. The main risk is the negative earnings trend, with a net income of -16,899,000 USD in Q2 2026, which investors should monitor closely.